Amgen, headquartered in Thousand Oaks, California, is a biotechnology company employing 26,700 staff, focusing on developing human therapeutics for high unmet medical needs. Its product portfolio includes Aranesp, ENBREL, and Prolia, among others.
AMGN has been in the news recently: Amgen (AMGN) is facing investor caution, as recent reports indicate a bearish outlook on the company's future. Additionally, Matthew C Busch, a VP at Amgen, sold a significant number of shares on May 7, according to an SEC filing.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
